Trials underpinning approval for a new listing for gout reflect a problem in current management.
Alternative sampling option, longer interval, increased entry age and a national register among changes to take effect in 2017.
A new PBS listing for second-line treatment of chronic symptomatic gout associated with hyperuricaemia.
From 1 August 2015 the PBS listing for apixaban was extended to include treatment of deep vein throbosis and pulmonary embolism, collectively referred to as venous thromboembolism.
From 1 October 2015 the PBS listing of exenatide is extended to allow triple therapy in combination with insulin and metformin type 2 diabetes.
From 1 July 2015 prescribing arrangements for PBS S100 medicines for HIV antiretroviral therapy, hepatitis B medicines and clozapine change to reflect that many taking these are managed in the community setting.
To encourage the quality use of testing under Medicare, vitamin B12 and serum folate are now listed as separate items, and vitamin D testing has been split into two types: testing for deficiency and testing for hypercalcaemia.